Skip to main content
. Author manuscript; available in PMC: 2022 Jun 8.
Published in final edited form as: Urol Oncol. 2020 Dec 8;39(2):134.e1–134.e8. doi: 10.1016/j.urolonc.2020.11.019

Table 3.

Recurrences and functional outcomes for patients with unilateral and bilateral masses

Unilateral Adrenal Mass (N = 45)
Bilateral Adrenal Mass (N = 21)
Partial Adrenalectomy
(N = 22)
Total Adrenalectomy
(N = 23)
Partial Adrenalectomy
(N = 13)
Total Adrenalectomy
(N = 8)
Evaluation of Patients with Recurrences
 Patients with at least one additional pheo: N, (%) 7(32) 6 (26) 4 (31) 0 (0)
Years to first additional pheo: mean, (range) 5.6 (0.2–15.0) 5.4 (0.9–14.3) 13.2 (0.4–34.6)
Patients with multiple additional pheo: N, (%) 3 (14) 4 (17) 0 (0) 0
Evaluation of Total Number of Recurrences
 Total ipsilateral recurrences: N, (%) 3 (15) 1 (4) 3 (38) 0 (0)
Years to ipsilateral recurrence: mean (range) 3.8 (0.4–8.0) 3.3 (3.3–3.3) 13.2 (0.4–34.6)
Total contralateral pheo: N, (%) 6 (23) 6 (26)
Years to contralateral pheo: mean (range) 6.0 (0.2–15.0) 6.1 (1.2–12.7)
Total extra adrenal pheo: N (%) 2 (9) 4 (17) 0 (0) 0
Years to extra adrenal pheo: mean (range) 7.2 (0.4–8.5) 4.7 (0.9–14.3)
Functional Outcomes
 Require steroid replacement: N, (%) 0 (0) 2 (8) 1 (13) 8 (100)